FDA Approves First Adjuvant Therapy for Renal Cell Carcinoma

The FDA has approved sunitinib malate (Sutent) as an adjuvant therapy for adults at risk for recurrent renal cell carcinoma following nephrectomy. Sunitinib, a kinase...
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news